AR091586A1 - DERIVED FROM AMIDA OR ITS SALT AS AN INHIBITOR OF COLAGENO PRODUCTION - Google Patents
DERIVED FROM AMIDA OR ITS SALT AS AN INHIBITOR OF COLAGENO PRODUCTIONInfo
- Publication number
- AR091586A1 AR091586A1 ARP130102277A AR091586A1 AR 091586 A1 AR091586 A1 AR 091586A1 AR P130102277 A ARP130102277 A AR P130102277A AR 091586 A1 AR091586 A1 AR 091586A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- formula
- represented
- atom
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 102000008186 Collagen Human genes 0.000 abstract 3
- 108010035532 Collagen Proteins 0.000 abstract 3
- 229920001436 collagen Polymers 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000037319 collagen production Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un agente para el tratamiento como prevención o terapia de enfermedades asociadas con hiperproducción de colágeno, que tiene una acción inhibidora de la producción de colágeno. El compuesto o una de sus sales has una acción inhibidora de la producción de colágeno y es de utilidad para el tratamiento como prevención o terapia de enfermedades asociadas con hiperproducción de colágeno, tales como fibrosis pulmonar, esclerodermia, nefroesclerosis y cirrosis. Reivindicación 1: Un compuesto representado por la fórmula [1] o una de sus sales, caracterizado porque R¹ representa un grupo arilo opcionalmente sustituido con uno o varios grupos seleccionados de un grupo sustituyente a, un grupo heterocíclico monocíclico opcionalmente sustituido con uno o varios grupos seleccionados del grupo sustituyente a o un grupo heterocíclico bicíclico opcionalmente sustituido; uno de R² y R³ representa un grupo representado por la fórmula -X¹-R⁶ (en donde X¹ representa un átomo de oxígeno, un átomo de azufre, un grupo imino opcionalmente protegido, un grupo alquileno C₁₋₆ opcionalmente sustituido, un grupo alquenileno C₂₋₆ opcionalmente sustituido, un grupo alquinileno C₂₋₆ opcionalmente sustituido o un enlace; y R⁶ representa un grupo arilo opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido o un grupo cicloalquilo C₃₋₈ opcionalmente sustituido); el otro de R² y R³ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ opcionalmente sustituido, un grupo alcoxi C₁₋₆ opcionalmente sustituido, un grupo arilo opcionalmente sustituido o un grupo representado por la fórmula -X¹-R⁶ (en donde X¹ y R⁶ tienen los mismos significados que los descritos con anterioridad); X² representa un grupo alquileno C₁₋₆ opcionalmente sustituido, un grupo alquenileno C₂₋₆ opcionalmente sustituido, un grupo alquinileno C₂₋₆ opcionalmente sustituido o un enlace; Z¹ y Z², que son iguales o diferentes, representan cada uno un átomo de nitrógeno o un grupo representado por la fórmula C-R⁷ (en donde R⁷ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ opcionalmente sustituido o un grupo alcoxi C₁₋₆ opcionalmente sustituido); e Y representa -N=N-, -S(O)O-, -C(O)-O-, -C(O)-S- o -C(S)-O- (en donde el enlace en el lado izquierdo de cada grupo se une con NH), en donde cuando R³ representa un grupo representado por la fórmula -X¹-R⁶ (en donde X¹ y R⁶ tienen los mismos significados que los descritos con anterioridad), Y representa -S(O)-O-, -C(O)-O-, -C(O)-S- o -C(S)-O- (en donde el enlace en el lado izquierdo de cada grupo se une con NH) y X² representa un enlace, en donde grupo sustituyente a: un átomo de halógeno, un grupo nitro, un grupo alquilo C₁₋₆ opcionalmente sustituido, un grupo alquenilo C₂₋₆ opcionalmente sustituido, un grupo alquinilo C₂₋₆ opcionalmente sustituido, un grupo alcoxi C₁₋₆ opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo amino cíclico opcionalmente sustituido y un grupo representado por la fórmula -NR⁴R⁵ (en donde R⁴ y R⁵, que son iguales o diferentes, representan cada uno un átomo de hidrógeno o un grupo alquilo C₁₋₆ opcionalmente sustituido).An agent for the treatment as prevention or therapy of diseases associated with collagen hyperproduction, which has an inhibitory action of collagen production. The compound or one of its salts has an inhibitory action on the production of collagen and is useful for the treatment as prevention or therapy of diseases associated with collagen hyperproduction, such as pulmonary fibrosis, scleroderma, nephrosclerosis and cirrhosis. Claim 1: A compound represented by the formula [1] or one of its salts, characterized in that R¹ represents an aryl group optionally substituted with one or more groups selected from a substituent group a, a monocyclic heterocyclic group optionally substituted with one or more groups selected from the substituent group a or an optionally substituted bicyclic heterocyclic group; one of R² and R³ represents a group represented by the formula -X¹-R⁶ (where X¹ represents an oxygen atom, a sulfur atom, an optionally protected imino group, an optionally substituted C₁₋₆ alkylene group, a C₂ alkenylene group ₋₆ optionally substituted, an optionally substituted C₂₋₆ alkynylene group or a bond; and R⁶ represents an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted C₃₋₈ cycloalkyl group); the other of R² and R³ represents a hydrogen atom, a halogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted aryl group or a group represented by the formula -X¹- R⁶ (where X¹ and R⁶ have the same meanings as described above); X² represents an optionally substituted C₁₋₆ alkylene group, an optionally substituted C₂₋₆ alkenylene group, an optionally substituted C₂₋₆ alkynylene group or a bond; Z¹ and Z², which are the same or different, each represent a nitrogen atom or a group represented by the formula C-R⁷ (where R⁷ represents a hydrogen atom, a halogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₁₋₆ alkoxy group); and Y represents -N = N-, -S (O) O-, -C (O) -O-, -C (O) -S- or -C (S) -O- (where the link in the left side of each group joins with NH), where when R³ represents a group represented by the formula -X¹-R⁶ (where X¹ and R⁶ have the same meanings as described above), Y represents -S (O) -O-, -C (O) -O-, -C (O) -S- or -C (S) -O- (where the link on the left side of each group joins with NH) and X² represents a bond, wherein substituent group to: a halogen atom, a nitro group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, a C₁₋ alkoxy group ₆ optionally substituted, an optionally substituted heterocyclic group, an optionally substituted cyclic amino group and a group represented by the formula -NR⁴R⁵ (where R⁴ and R⁵, which are the same or different, each represent a hydrogen atom or a group C₁₋₆ alkyl optionally substituted).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012145213 | 2012-06-28 | ||
| JP2013052626 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091586A1 true AR091586A1 (en) | 2015-02-11 |
Family
ID=49783260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102277 AR091586A1 (en) | 2012-06-28 | 2013-06-27 | DERIVED FROM AMIDA OR ITS SALT AS AN INHIBITOR OF COLAGENO PRODUCTION |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR091586A1 (en) |
| TW (1) | TW201406736A (en) |
| WO (1) | WO2014003124A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| TN2016000253A1 (en) | 2013-12-19 | 2017-10-06 | Novartis Ag | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis. |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2017147701A1 (en) * | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| MX2018010374A (en) * | 2016-03-01 | 2019-03-28 | Propellon Therapeutics Inc | Inhibitors of wdr5 protein-protein binding. |
| JP2025159734A (en) * | 2022-08-31 | 2025-10-22 | 学校法人東京理科大学 | Cancer therapy using a combination of anti-fibrotic small molecule compounds and immune checkpoint regulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007271734B2 (en) * | 2006-07-05 | 2012-03-29 | Certa Therapeutics Pty. Ltd. | Therapeutic compounds |
| US7951806B2 (en) * | 2007-07-25 | 2011-05-31 | Renascience Co., Ltd. | Plasminogen activator inhibitor-1 inhibitor |
| NZ594195A (en) * | 2009-01-30 | 2013-04-26 | Toyama Chemical Co Ltd | N-acyl anthranilic acid derivative or salt thereof |
-
2013
- 2013-06-27 AR ARP130102277 patent/AR091586A1/en unknown
- 2013-06-27 TW TW102122970A patent/TW201406736A/en unknown
- 2013-06-27 WO PCT/JP2013/067668 patent/WO2014003124A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014003124A1 (en) | 2014-01-03 |
| TW201406736A (en) | 2014-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091586A1 (en) | DERIVED FROM AMIDA OR ITS SALT AS AN INHIBITOR OF COLAGENO PRODUCTION | |
| JOP20190070B1 (en) | Benzo[b]thiophene compounds as agonists that stimulate the protein of interferon genes | |
| PE20170206A1 (en) | SPIROCYCLIC INHIBITORS SUBSTITUTE FOR AUTOTAXIN | |
| AR094277A1 (en) | FUMARATE DERIVATIVES REPLACED WITH DEUTERIO | |
| EA201590661A1 (en) | AZACHINASOLINE INHIBITORS OF ATYPICAL PROTEINKINASE C | |
| AR109179A1 (en) | DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS | |
| BR112015009850A2 (en) | heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| MX2017014613A (en) | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase. | |
| AR106041A1 (en) | MODULATORS OF THE CORE PROTEIN OF HEPATITIS B | |
| BR112015018509A2 (en) | imidazo pyridine compounds | |
| BR112014003237A2 (en) | indazole compounds, compositions and methods of use | |
| PE20150734A1 (en) | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | |
| AR095823A1 (en) | CYCLOPROPANAMINE COMPOUND AND USE OF THE SAME | |
| EA201201648A1 (en) | SGC STIMULATORS | |
| AR094812A1 (en) | DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR | |
| MX2010004293A (en) | Wo 2009087305 a1 20090716. | |
| PE20161225A1 (en) | 2-AMINO-3,5,5-TRIFLUORO-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| MX2017009625A (en) | MACROCICLICAL COMPOUNDS AS INHIBITORS OF KINASES ASSOCIATED WITH THE INTERLEUCINE RECEIVER1 / 4 (IRAK1 / 4) AND USES OF THE SAME. | |
| AR097082A1 (en) | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | |
| PE20151718A1 (en) | PYRIDINYLPIRAZOLOQUINOLINE COMPOUNDS | |
| MX391489B (en) | HETEROCYCLIC MCT4 INHIBITORS. | |
| BR112015029348A2 (en) | bace inhibitors | |
| MX2016015467A (en) | Carbonitrile derivatives as selective androgen receptor modulators. | |
| AR100748A1 (en) | DERIVED FROM 2-ACILAMINOTIAZOL OR ITS SALT | |
| AR104262A1 (en) | CHROMENE DERIVATIVES AS INHIBITORS OF PHOSFOINOSITIDO-3 KINASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |